OneSource Specialty Pharma Ltd 11 Jun 2025 12:00 AM
OneSource collaborates with Xbrane Biopharma AB,
OneSource Specialty Pharma and Xbrane Biopharma AB, a Sweden-headquartered biotechnology company, today announced a partnership focused on the commercial manufacturing of Xbrane`s biosimilar portfolio. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference products. The lead candidate Ximluci (a ranibizumab biosimilar) is granted market authorization approval in Europe (launched in 2023) and is now under the approval process for the U.S. launch. As part of the agreement, Xbrane will tech transfer its select product(s) to OneSource`s state-of the-art integrated Drug Substance and Drug Product (DS/DP) facility in Bangalore, India. The collaboration aims to strengthen Xbrane`s global supply chain, while enabling OneSource to accelerate regulatory approvals, including from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), for its biologics drug substance facility. As part of the collaboration, OneSource has also participated in Xbrane`s latest funding round, reinforcing the long-term alignment between the two companies. Powered by Capital Market - Live News
OneSource Specialty Pharma Ltd 04 Jun 2025 12:00 AM
OneSource receives ratings action from India Ratings & Research,
OneSource Specialty Pharma announced that India Ratings & Research has assigned the credit rating IND A-; Positive/ IND A1 for bank facilities availed by the company. Powered by Capital Market - Live News
OneSource Specialty Pharma Ltd 06 May 2025 12:00 AM
OneSource Specialty Pharma reports consolidated net profit of Rs 98.50 crore in the March 2025 quarter,
Net profit of OneSource Specialty Pharma reported to Rs 98.50 crore in the quarter ended March 2025 as against net loss of Rs 40.17 crore during the previous quarter ended March 2024. Sales rose 482.38% to Rs 425.95 crore in the quarter ended March 2025 as against Rs 73.14 crore during the previous quarter ended March 2024.For the full year,net loss reported to Rs 17.97 crore in the year ended March 2025 as against net loss of Rs 391.17 crore during the previous year ended March 2024. Sales rose 740.42% to Rs 1444.85 crore in the year ended March 2025 as against Rs 171.92 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales425.9573.14 482 1444.85171.92 740 OPM %42.85-3.84 -32.29-51.33 - PBDT151.99-20.62 LP 317.67-173.46 LP PBT83.50-40.15 LP 43.78-249.76 LP NP98.50-40.17 LP -17.97-391.17 95 Powered by Capital Market - Live News
OneSource Specialty Pharma Ltd 30 Apr 2025 12:00 AM
OneSource Specialty Pharma to convene board meeting,
OneSource Specialty Pharma will hold a meeting of the Board of Directors of the Company on 5 May 2025.Powered by Capital Market - Live News
OneSource Specialty Pharma Ltd 10 Apr 2025 12:00 AM
OneSource receives Brazilian regulatory approval for its flagship Unit 2,
OneSource Specialty Pharma today announced that its flagship Unit 2 facility in Bengaluru has been granted Good Manufacturing Practices (GMP) certification by ANVISA, the Brazilian Health Regulatory Agency, following a successful regulatory inspection held in Nov 2024. This approval marks a significant milestone in OneSource`s ongoing commitment to quality and regulatory compliance. Unit 2 is OneSource`s flagship site dedicated to manufacturing high quality Biologics drug substance and finished products including Drug Device Combinations (DDC) and other injectable products.Powered by Capital Market - Live News
Subscribe for our
newsletter
Open Account Now